Occurrence and characterization of everolimus adverse events during first and subsequent cycles in the treatment of metastatic breast cancer

被引：0
|
作者：
Craig A. Vargo
Michael J. Berger
Gary Phillips
Ewa Mrozek
机构：
[1] The Ohio State University Wexner Medical Center,Department of Pharmacy, The James Cancer Hospital and Solove Research Institute
[2] The Ohio State University,Center for Biostatistics
[3] The Ohio State University Wexner Medical Center,Division of Medical Oncology, Department of Internal Medicine
来源：
Supportive Care in Cancer | 2016年 / 24卷
关键词：
Everolimus; Adverse events; Breast cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2913 / 2918
页数：5
相关论文
共 50 条
  • [1] Occurrence and characterization of everolimus adverse events during first and subsequent cycles in the treatment of metastatic breast cancer
    Vargo, Craig A.
    Berger, Michael J.
    Phillips, Gary
    Mrozek, Ewa
    SUPPORTIVE CARE IN CANCER, 2016, 24 (07) : 2913 - 2918
  • [2] Everolimus in the Treatment of Metastatic Breast Cancer
    Royce, Melanie E.
    Osman, Diaa
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2015, 9 : 73 - 79
  • [3] Diagnostic challenges of respiratory adverse events during everolimus treatment
    Willemsen, Annelieke E. C. A. B.
    De Vos, Filip Y.
    Jansen, Anne
    de Boer, Maaike
    Tjan-Heijnen, Vivianne C. G.
    van Herpen, Carla M. L.
    TARGETED ONCOLOGY, 2014, 9 (03) : 287 - 291
  • [4] Diagnostic challenges of respiratory adverse events during everolimus treatment
    Annelieke E. C. A. B. Willemsen
    Filip Y. De Vos
    Anne Jansen
    Maaike de Boer
    Vivianne C. G. Tjan-Heijnen
    Carla M. L. van Herpen
    Targeted Oncology, 2014, 9 : 287 - 291
  • [5] COST OF ADVERSE EVENTS DURING TREATMENT WITH EVEROLIMUS PLUS EXEMESTANE OR SINGLE-AGENT CHEMOTHERAPY IN PATIENTS WITH ADVANCED BREAST CANCER
    Campone, M.
    Yang, H.
    Faust, E.
    Kageleiry, A.
    Signorovitch, J.
    Zhang, J.
    Gao, H.
    VALUE IN HEALTH, 2013, 16 (07) : A401 - A402
  • [6] Mycobacteria infection may occur during everolimus treatment in metastatic breast cancer patients
    Liu, Chien-Ting
    Chen, Yen-Yang
    Li, Shan-Hsuan
    Wu, Shih-Chung
    Rau, Kun-Ming
    ANNALS OF ONCOLOGY, 2017, 28 : 97 - 97
  • [7] Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer
    Kuik, Kelvin Teck-Hong
    Trubiano, Jason
    Worth, Leon J.
    Harun, Nur-shirin
    Steinfort, Daniel
    Johnson, Douglas
    MEDICAL MYCOLOGY CASE REPORTS, 2014, 6 : 34 - 36
  • [8] Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line
    Pouget, Melanie
    Abrial, Catherine
    Planchat, Eloise
    Van Praagh, Isabelle
    Arbre, Marie
    Kwiatkowski, Fabrice
    Dubray-Longeras, Pascale
    Devaud, Herve
    Dohou, Joyce
    Herviou, Pauline
    Mahammedi, Hakim
    Durando, Xavier
    Chollet, Philippe
    Mouret-Reynier, Marie-Ange
    ONCOLOGY, 2015, 89 (06) : 319 - 331
  • [9] The cost of treatment-related adverse events in metastatic breast cancer therapy: Taxanes versus capecitabine.
    Hansen, Ryan N.
    Brammer, Melissa G.
    Ramsey, Scott David
    Lalla, Deepa
    Hurvitz, Sara A.
    Sullivan, Sean D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Treatment patterns and associated adverse events among patients with metastatic triple-negative breast cancer.
    Kaklamani, Virginia G.
    Schultz, Neil M.
    Irwin, Debra E.
    Fulcher, Nicole
    Noxon, Virginia
    Wu, Jun
    Pandya, Bhavik J.
    Kim, Ruth
    Barley, Arie
    Flanders, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345